Cuprina Holdings
Manufacturing · Singapore · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1090 Lower Delta Road #06-08, Central Si...Phone Number
+6585127275Website
www.cuprina.comRevenue
<$5 MillionStock Symbol
CUPRIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Cuprina Holdings
Cuprina is a Singapore-based MedTech company that specializes in the development of products to treat chronic wounds.MEDIFLY, a bio-dressing made of live, medical-grade maggots, is used by private and public hospitals in Singapore and Hong Kong to disinfect and debride chronic wounds, known as Maggot Debridement Therapy (MDT).Our product is clinically proven to reduce amputation rates and eliminate infections in chronic wounds, especially diabetic foot ulcers and pressure ulcers.We are ISO 13485 certified and our MEDIFLY products are HSA registered as class C medical devices.We are also developing collagen wound dressing products from bullfrog skin, which has shown promising results in its ability to heal wounds.Explore more
Cuprina Holdings Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cuprina Holdings your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Cuprina Holdings launches new products
Check if Cuprina Holdings has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Cuprina Holdings
Funding: Get notified immidiatlly once Cuprina Holdings has new funding data
Website visits: Recent activity has been detected on your website
Check out if Cuprina Holdings is spiking on competitors!
Click to see if Cuprina Holdings had a recent Job posting/layoffs
Earning: See what the market has to say on Cuprina Holdings recently announced quarterly report
Cuprina Holdings, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Cuprina Holdings is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cuprina Holdings is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cuprina Holdings.
Cuprina Holdings News & Media
Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering
SINGAPORE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced the closing of its previously announced public offering of an aggregate 4,322,489 Class A Ordinary Shares (“the Offering”) at a price of $1.15 per share (“the Offering Price”) to the public, for a total of approximCuprina Holdings (Cayman) Limited Announces Pricing of $4.97 million Public Offering
SINGAPORE, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced the pricing of its firm commitment public offering of an aggregate 4,322,489 shares of its Class A Ordinary Shares (“the Offering”), all of which are being offered by CUPR at a public offering price of $1.15 per shCuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product
SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that an indirectly wholly-owned subsidiary of the Company, Cuprina Pte. Ltd. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MEDIFLY Maggots™, its medical-grade Lucilia cuprina larvaeCuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements
SINGAPORE, June 12, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that on June 11, 2026 it has regained compliance with the Nasdaq Capital Markets Listing Requirements.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cuprina Holdings
Sign Up For FreeTo access detailed company insights
Cuprina is a Singapore-based MedTech company that specializes in the development of products to treat chronic wounds.MEDIFLY, a bio-dressing made of live, medical-grade maggots, is used by private and public hospitals in Singapore and Hong Kong to disinfect and debride chronic wounds, known as Maggot Debridement Therapy (MDT).Our product is clinica... Read More
